505 (b) (2) approvals in May 2025

There are three 505(b)(2) NDAs approved by the USFDA and one NDA that received tentative approval from the USFDA in May 2025. The details are as follows.


More details can also be found in the API and IP newsletter published by us. 


Comments

Post a Comment

Popular posts from this blog

US FDA's Compliance Program for Drug Quality Assurance, with a focus on Active Pharmaceutical Ingredient (API) process

The USFDA released a document on 01 August 2025 outlining a Compliance Program for Drug Quality Assurance, with a focus on Active Pharmaceutical Ingredient (API) process inspections. The program aims to ensure that APIs are manufactured following Current Good Manufacturing Practice (CGMP) standards, thereby protecting the quality, identity, and purity of the drugs. Key Elements Purpose: To detail a risk-based inspection strategy for API manufacturing facilities, ensuring compliance with CGMP standards. Scope: Applies to the manufacturing of APIs for human drug products, including small molecules, polypeptides, antibiotics, and other APIs produced by chemical synthesis or microbial fermentation. Excludes APIs for blood, vaccines, allergenics, tissues, and cellular and gene therapies. Implementation Date: 09/02/2025 Revisions: Includes elements from the International Council for Harmonisation (ICH) guidances for industry, specifically Q9(R1) Quality Risk Management (May 2023), Q10 Ph...
Read more

Summary of FDA inspection of Hetero Labs Unit-X

Image
General Information: Facility: Hetero Labs Limited, Unit-IX, located in Narasapuram Village, Andhra Pradesh, India. Inspection Dates: 09/19-26/2025. Type of Establishment: API (Active Pharmaceutical Ingredient) Manufacturer. Key Observations: 1. Unregistered Testing Laboratory: The facility used an unregistered testing laboratory for API testing, which was not referenced in their Drug Master Files (DMFs). This laboratory was located away from the main facility. Finished API samples with matching batch numbers and dates were discovered, indicating collaboration with the unregistered lab. The firm did not have a quality agreement established with this unregistered testing facility conducting analysis on products manufactured by your firm. Multiple examples of API intermediate samples were found at the unregistered testing laboratory. Numerous uncontrolled notebook pages containing analytical test results for APIs and API intermediates manufactured at this facility were found in the ...
Read more

FDA form 483 observations: NATCO Pharma

FDA form 483 observations: NATCO Pharma General Information: • Company: NATCO Pharma Limited, Pharma Division, Kothur Village, Rangareddy,           Telangana, India • Inspection Dates: 06/09/2025 - 06/19/2025 • Products manufactured: Sterile and Non-Sterile Drug Manufacturers   Oral solid dosages, including Cytotoxic Orals Cytotoxic Injectables Pre-filled Syringes Key Observations: 1. Environmental Monitoring Deficiencies (Observation 1): The firm's system for monitoring environmental conditions in aseptic processing areas is deficient. Electronic data for non-viable particle (NVP) counts used in environmental monitoring and cleanroom qualification is not adequately reviewed. Discrepancies exist between electronic data and official hardcopy results for NVP, affecting multiple batches between 11/02/2023 and 04/16/2024, where results were altered. Operators saved data on USB drives, potentially allowing data manipulation, which indicates a gap in dat...
Read more